Zoetis to Acquire VitalRADS, Boosting Diagnostic Capabilities
ZTS is trading near its 52-week low of $71.47 (5.1% above the low).
Summary
Zoetis is acquiring VitalRADS, a move that accelerates its diagnostic capabilities. The deal comes two months after the company slashed its full-year guidance and faces a class action lawsuit over alleged misrepresentations. This acquisition signals a strategic push into diagnostics, potentially offsetting recent headwinds. No financial terms were disclosed, leaving the deal's materiality uncertain. The market will watch for integration details and any impact on the lowered 2026 outlook.
At the time of this announcement, ZTS was trading at $75.13 on NYSE in the Life Sciences sector, with a market capitalization of approximately $31.6B. The 52-week trading range was $71.47 to $160.48. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.